Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEY2153 in Early Alzheimer's Disease
NCT06885567Phase 2Not yet recruiting
- Sponsor
- BeyondBio Inc.
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BEY2153 in Alzheimer's disease (AD) (3 arms), sponsored by BeyondBio Inc. Primary endpoint: Treatment Emergent Adverse Events and Serious Adverse Events. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
BEY2153
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06885567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885567.